Chemistry:AG-270
From HandWiki
AG-270 is an experimental drug which acts as an inhibitor of the methionine adenosyltransferase 2α (MAT2A) enzyme, which is important for the development of some types of cancer. AG-270 has reached early stage human clinical trials.[1][2][3][4][5]
References
- ↑ "MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage". Cancer Cell 39 (2): 209–224.e11. February 2021. doi:10.1016/j.ccell.2020.12.010. PMID 33450196.
- ↑ "Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion". Journal of Medicinal Chemistry 64 (8): 4430–4449. April 2021. doi:10.1021/acs.jmedchem.0c01895. PMID 33829783.
- ↑ "Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy". Current Opinion in Oncology 34 (5): 546–551. September 2022. doi:10.1097/CCO.0000000000000870. PMID 35788128.
- ↑ "The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity". Biochemical and Biophysical Research Communications 716. July 2024. doi:10.1016/j.bbrc.2024.150011. PMID 38704890.
- ↑ "MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial". Nature Communications 16 (1): 423. January 2025. doi:10.1038/s41467-024-55316-5. PMID 39762248. Bibcode: 2025NatCo..16..423G.
 |  |
